Paolo Anderlini, MD

home / authors / paolo-anderlini-md

Articles

Paolo Anderlini, MD;Donna Przepiorka, MD, PhD

April 1st 2005

Allogeneic marrow transplantation is used to reconstitute hematopoiesis in patients who have received myeloablative therapy for a hematologic malignancy or in patients with irreversible marrow failure, to reconstitute the immune system in patients with severe immunodeficiency, and to normalize metabolism in patients with select inherited metabolic deficiency disorders.

Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation

Richard Champlin, MD;Issa F. Khouri, MD;Paolo Anderlini, MD;Marcos J. G. De Lima, MD;Chitra Hosing, MD;John Mcmannis, PhD;Jeffrey Molldrem, MD;Naoto Ueno, MD;Sergio Giralt, MD

January 1st 2003

High-dose myeloablative therapy with allogeneic hematopoietictransplantation is an effective treatment for hematologic malignancies,but this approach is associated with a high risk of complications.The use of relatively nontoxic, nonmyeloablative, or reduced-intensitypreparative regimens still allows engraftment and the generation ofgraft-vs-malignancy effects, is potentially curative for susceptiblemalignancies, and reduces the risk of treatment-related morbidity.Two general strategies along these lines have emerged, based on theuse of (1) immunosuppressive chemotherapeutic drugs, usually apurine analog in combination with an alkylating agent, and (2) lowdosetotal body irradiation, alone or in combination with fludarabine(Fludara).